KPV
Alpha-MSH-derived tripeptide. Potent anti-inflammatory for gut health, IBD, and skin conditions.
Last updated: June 2026
Category
Healing & Recovery
Frequency
1 to 2x daily (community practice, no trial)
Research
Preclinical + Phase 2What is KPV?
KPV is a tripeptide (Lysine-Proline-Valine) derived from the C-terminal of Alpha-Melanocyte-Stimulating Hormone (α-MSH). It contains the core anti-inflammatory activity of α-MSH in a minimal 3 amino acid sequence, making it highly stable, well-tolerated, and capable of oral delivery. Browse the full peptide library for related healing compounds.
KPV is studied for anti-inflammatory effects, particularly in the gut and skin. It is commonly paired with BPC-157 in community practice, though no study has tested that combination. Studies have shown it activates melanocortin receptors (specifically MC1-R, MC3-R, and MC5-R) in immune cells, producing a powerful anti-inflammatory response without the side effects of corticosteroids.
KPV is gaining significant attention as a potential treatment for Inflammatory Bowel Disease (IBD), including both Crohn's disease and Ulcerative Colitis. For systemic healing, consider combining with TB-500. Unlike BPC-157 which heals tissue mechanically, KPV specifically targets the immune-mediated inflammation at the root of IBD. For broader immune system support, thymosin alpha-1 targets T-cell function and chronic immune resilience.
How It Works
Melanocortin Receptor Activation: KPV activates MC1-R, MC3-R, and MC5-R receptors on immune cells (particularly macrophages and dendritic cells), suppressing the production of pro-inflammatory cytokines.
NF-κB Inhibition: KPV inhibits the NF-κB transcription factor, the master regulator of the inflammatory response, directly in immune and epithelial cells.
Intestinal Epithelial Healing: KPV promotes intestinal epithelial cell recovery and barrier function restoration, complementing its anti-inflammatory action in the gut.
Benefits
- Potent anti-inflammatory for gut (IBD, Crohn's, IBS)
- Skin inflammation reduction (psoriasis, dermatitis, acne)
- Wound healing acceleration
- Can be taken orally for gut effects
- Well-tolerated with excellent safety profile
- Systemic anti-inflammatory via injection
- Commonly paired with BPC-157 in community practice (no study has tested the combination)
Dosing Described in Research and Labels
| Phase | Dose | Frequency | Duration |
|---|---|---|---|
| Systemic or gut (research) | No established human dose | Oral or subcutaneous (research) | Not established |
| Topical (research) | Varies by formulation | Topical | Not established |
These figures summarise what published research and approved labels describe. They are educational, not a recommendation or a personal protocol. Any dose, schedule, or decision to use a compound belongs with a licensed prescriber.
Side Effects
Common
- ⚠Generally very well tolerated
- ⚠Mild injection site reaction
- ⚠Mild nausea if oral dose taken without food
Rare
- •Possible skin pigmentation change (melanocortin receptor, theoretical)
Who Should NOT Use KPV
- ✕Active skin cancer (melanocortin receptor activation)
- ✕Pregnancy or breastfeeding
- ✕On immunosuppressive therapy (consult physician)
What to Expect
Reduced bloating and cramping within the first week, and reduced redness for skin use, are commonly reported (community practice, no trial).
Reports describe symptoms easing over this window (community practice, no trial). No controlled human trial has measured symptom scores for KPV in any condition, so there is no clinical figure to compare against.
Some reports describe sustained improvement (community practice, no trial). Remission in inflammatory bowel disease is a clinical endpoint that requires diagnosis and monitoring, and no trial has measured it for KPV. This page publishes no remission or clearance rates because none exist.
Notes from Ho Chi Minh City
Living in Vietnam means street food, and street food eventually means a stretch of low-grade gut inflammation that probiotics do not fully settle. KPV's research context is exactly that anti-inflammatory niche, described in an oral form taken on an empty stomach for bioavailability. It is often discussed alongside BPC-157 for more structural gut issues like a flare from spicy food. Handling is simple: the powder is kept refrigerated and reconstituted in small, fresh batches. What dose, what schedule, and whether to combine it with anything else are decisions for a licensed prescriber rather than a routine copied from a forum.
FAQ
Q: Should I use KPV or BPC-157 for gut issues?
A: No trial has compared them and none has tested them together, in animals or in people, so a page claiming the two are best combined is stating a preference rather than a result. What the studies describe is different: BPC-157 is associated in animal models with tissue repair and new blood vessel formation, KPV with dampening inflammatory signalling through melanocortin receptors and NF-kappaB. Neither is an approved treatment for inflammatory bowel disease or any other gut condition anywhere. Inflammatory gut disease in particular is something to work through with a gastroenterologist, because the differential diagnosis matters more than the compound.
Q: Does oral KPV work as well as injectable?
A: No human trial has compared the two routes, so there is no basis for calling either one better. What has been published is preclinical: KPV was taken up by intestinal epithelial and immune cells through the PepT1 transporter, inhibited NF-kappaB signalling at nanomolar concentrations in cell culture, and reduced DSS-induced and TNBS-induced colitis in mice when added to their drinking water (mouse study, not a human dose, PMID 18061177). That is the origin of the argument for the oral route in gut conditions, and it is a mouse result. Matching a route to a condition is a clinical judgement rather than a general rule. Source from the community-verified supplier list.
Where to Get KPV in Vietnam
See our community-verified supplier list with COA verification and cold-chain shipping to Vietnam.
Related Peptides
Research & Sources
- Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease · Kannengiesser K, Maaser C, Heidemann J, et al. · Inflammatory Bowel Diseases (2008) (PMID: 18092346)
Demonstrates anti-inflammatory action of KPV in colitis models with reduced cytokine production and improved mucosal healing.
- Lysine-Proline-Valine (KPV): a tripeptide with anti-inflammatory and antimicrobial activity · Cutuli M, Cristiani S, Lipton JM, Catania A · Journal of Leukocyte Biology (2000) (PMID: 10985256)
Foundational paper showing KPV anti-inflammatory mechanism via melanocortin receptor activation in macrophages.
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation · Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. · Gastroenterology (2008) (PMID: 18061177)
Mouse model data supporting oral KPV efficacy in colitis, relevant to dosing the oral protocol.
- Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis · Xiao B, Xu Z, Viennois E, et al. · Molecular Therapy (2017) (PMID: 28143741)
Phase-relevant translational data showing site-specific KPV delivery improves outcomes in ulcerative colitis models.
Important Disclaimer
Educational content only. Not medical advice. Peptides discussed on this page are not approved by Vietnam’s Ministry of Health (Bộ Y Tế) or the Drug Administration of Vietnam (DAV) for the indications described. Research peptides are not stocked at Long Châu, Pharmacity, or any retail pharmacy in Vietnam. Consult a licensed physician before any use.